Compare Ginkgo Bioworks Holdings Inc (DNA) vs Symbotic Inc (SYM) Price & Performance

DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.

The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.

Symbotic Inc. (SYM) trades at $42.43, down 2.77% on the day, with technical indicators signaling a bearish trend. The company reported revenue of $2.25 billion in 2025 but posted a net loss of $16.94 million, though gross margins improved to 20.43%. Recent news highlights the acquisition of ARMS Innovations, expanding its AI-powered warehouse optimization solutions. Analyst consensus remains positive with a $57.50 price target, but mixed earnings performance and high valuation ratios present challenges.

Outlook: SYM shows potential in the growing robotics and automation sector, supported by strong operating cash flow and strategic acquisitions. However, profitability concerns, high EV/EBITDA of 240.06, and competitive pressures pose significant risks. Investors should weigh the bullish analyst sentiment against fundamental weaknesses and market volatility.